Daily use of an ‘antiviral gel’ may prevent genital herpes in women

genital herpes - tenofovir gel
Genital Herpes - Tenofovir Gel
According to a new study, Daily use of 1 percent tenofovir gel may prevent genital herpes in women.



The researchers examined the effect of vaginal tenofovir 1 percent gel use on the risk of acquiring herpes simplex virus type 2, or HSV-2 and found the results. The study was conducted through a secondary analysis of data or information from the VOICE study, the primary results of which were published in 2015.

The paper has been published in the Journal of Infectious Diseases.

Here, according to the Centers for disease control and prevention, more than one in six Americans ages 14 to 49 are infected with genital herpes. HSV-2 infection is the top most common cause of genital herpes and also enhances the risk of acquiring and transmitting HIV. No vaccine currently exists for HSV-2.

In addition, women are especially at risk of infection because it is more easily transmitted from an infected man to his female sex partner than vice versa. A product that protects against HSV-2(Herpes Simplex) could have an important public health impact.

Let’s talk about vagina gel: Of the 566 HSV-2-negative, the participants found that the overall use of vaginal tenofovir 1 percent gel was associated with a 40% reduction of HSV-2 acquisition.

Over the ‘follow-up period’, there are 92 new cases of ‘HSV-2’ occurred, with 77 in women with no ‘plasma tenofovir’ detected and 15 with plasma tenofovir. Here, ‘Tenofovir’ measured in plasma was used as a measure of gel use.

    ‘Douches’ and ‘feminine’ sprays claim to clean the vagina, but they have some very dangerous downsides



According to study, Marrazzo’s study reanalyzed data collected in the VOICE study, now if we talk specifically looking at the subgroup of women that adhered to daily gel usage in the vagina and their rate of HSV-2 acquisition relative to women who did not adhere to gel usage.

If we talk the original VOICE study, investigators studied HIV-1 ‘pre-exposure’ prophylaxis in ‘reproductive-age’ women in South Africa, Uganda and Zimbabwe. The Participants were asked to regularly use study products, including vaginal tenofovir 1% gel, but adherence was low.

Marrazzo said that while both studies focus on the same product, our study is distinct in various ways, such as the emphasis on daily usage. With our new findings, we can pay more attention or concentrate on or to studying products combining ‘tenofovir’ with other preventive materials in order to protect against ‘HSV-2’ and ‘HIV’ – the addressing both infections with multipurpose prevention products will maximize protective impact for women.
Previous
Next Post »